Table 2A. Estimates of overdiagnosis from the Malmö I trial, with and without inclusion of women age 45–54.
| Description | Calculation | Estimated overdiagnosis |
|---|---|---|
|
All women (age 45–69) | ||
| A. Excess cancers as a proportion of cancers diagnosed over whole follow up period in unscreened womena | 115/1205 | 9.5% |
| B. Excess cancers as a proportion of cancers diagnosed over whole follow up period in women invited for screening | 115/1320 | 8.7% |
| C. Excess cancers as a proportion of cancers diagnosed during screening period in women invited for screening | 115/741 | 15.5% |
| D. Excess cancers as a proportion of cancers detected by screening in women invited for screening (64% of all cancers detected in screened group)b |
115/474 |
24.3% |
|
Older women (age 55–69) | ||
| A. Excess cancers as a proportion of cancers diagnosed over whole follow up period in unscreened womena | 82/698 | 11.7% |
| B. Excess cancers as a proportion of cancers diagnosed over whole follow up period in women invited for screening | 82/780 | 10.5% |
| C. Excess cancers as a proportion of cancers diagnosed during screening period in women invited for screening | 82/438 | 18.7% |
| D. Excess cancers as a proportion of cancers detected by screening in women invited for screening (64% of all cancers detected in screened group)b | 82/282 | 29.1% |
a
Result reported by Zackrisson et al (Zackrisson, 2006)
b
i.e. excluding all interval cancers.